Markets Wired

Stock Technical Insights on Juno Therapeutics, Inc. (NASDAQ:JUNO)

July 24
10:35 2015

Juno Therapeutics, Inc. (NASDAQ:JUNO) (TREND ANALYSIS) shares were traded with no significant volume change. The stock closed last trading session at $51.65, up by 1.55%, with a volume of 2,109,316 shares against an average volume for the last 30 days of 2,759,802.

Stock Performance: Click here for a free comprehensive Trend Analysis Report

The company is currently valued at $4.75 billion and closed the last trading session at $51.65. The stock has 50-day moving average of $52.43.

Juno Therapeutics, Inc. (NASDAQ:JUNO) is currently trading 24.15% below its 52-week-high, 51.4% above its 52-week-low and in the range of $44.5-$64.35 over the past month. The 1-year range for the stock is $34.71-$69.28. Juno Therapeutics, Inc. (JUNO) has a price to book ratio of 13.23 versus Nasdaq average of 4.8. The company’s share price has underperformed the Nasdaq year to date by -1.24%.

Juno Therapeutics, Inc. (JUNO) current short interest stands at 4,850,389 shares. It has decreased by -18% from the same period of last month. Around 8.4% of the company’s shares, which are float, are short sold. With a 30-days average daily volume of 2,759,802 shares, the number of days required to cover the short positions stand at 1.2 days.

Stock Analyst Perspectives: Click here for a free Trend Analysis Report

There are currently seven analysts that we track that cover JUNO. Of those seven, four have a buy rating, three have a hold rating, and . On a consensus basis this yields to a Buy. The overall consensus target price stands at $64.2 which represents an upside of 22.17% from the last closing price of $52.55.

Indeed, Northland Securities Inc initiated coverage at outperform on July 21st, with a target price of $64, which represents an upside of 21.79% from the last closing price. Another research firm, Goldman Sachs, maintained their neutral stance on July 19th, with a target price of $51, which translates into a downside difference of -2.95%. Finally, Morgan Stanley maintained their In-Line stance on June 30th, with a target price of $54.

Company Profile

Juno Therapeutics Inc. operates as a clinical-stage biotechnology company. The Company focuses on developing immunotherapies for cancer and other research services.


About Author

Alex Larose

Alex Larose

Alex Larose covers Large and Mid Cap stocks. He joined Markets Wired in 2013 and assumed lead coverage of the several sectors in early 2014.

Related Articles